文献速递血液净化与透析

血液透析照护:转向以患者水平结局为核心的创新

Hemodialysis Care: Evolving to Enhance Patient-Level Outcomes.
PubMed 文献 · J Am Soc Nephrol · 2026-09-22

血液透析仍是全球肾脏替代治疗的主要方式,但死亡率、住院率、症状负担及健康相关生活质量受损仍然显著。综述指出,传统充分性指标优化带来的患者重要结局改善有限,应以临床结局、患者报告结局、安全性、公平性、可持续性和价值为框架评估透析技术。在线血液透析滤过(HDF)在体外治疗中证据最强,高容量在线HDF较高通量血液透析可能改善生存,但获益在无法达到高对流量的患者中不确定。

要点

  • 透析创新应从替代终点转向患者重要结局,生理合理性和替代指标改善不足以支持广泛采用。
  • 高容量在线血液透析滤过较高通量血液透析有更好的生存证据,但受限于能否达到高对流容量及实施条件。
  • 未来需开展比较效果研究、实施科学、真实世界证据,并常规整合标准化患者报告结局。

核心结论

  • 当前证据支持将透析创新从替代终点转向对患者有意义的结局,生理合理性和替代指标改善本身不应作为广泛采用的依据。

研究设计与样本

  • 本文为综述,评估当代体外透析模式与新兴技术,采用基于结局的框架并纳入实施、卫生系统影响和患者优先事项。

主要发现

  • 高通量血液透析是当前标准治疗,尽管达到现代充分性目标,但并未一致地与较低全因死亡率相关。
  • 中截留量膜、吸附型方法、个体化日程及便携、可穿戴或植入式技术具有生理学依据,可能改善部分替代指标,但 meaningful 临床获益证据仍有限。
  • 在线血液透析滤过在体外治疗中证据最强,随机试验和个体参与者数据荟萃分析提示高容量在线HDF较高通量血液透析生存更好,并有患者报告和成本效果证据支持。
  • CONVINCE研究中患者达到高对流容量,对于无法达到这些目标者获益不确定,实施取决于基础设施、报销、监管和质量保证。

临床怎么用

  • 临床评估透析技术时应关注生存、住院、症状和功能状态等患者重要结局,而非仅依赖溶质清除等替代指标。
  • 考虑在线血液透析滤过时需确保能达到高对流容量,并评估本地基础设施、报销和质量管理条件。

局限性

  • 在线血液透析滤过的获益在无法达到高对流容量的患者中不确定。
  • 多种新兴技术仅显示替代指标改善,缺乏 meaningful 临床获益证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemodialysis remains the predominant form of kidney replacement therapy worldwide, yet mortality, hospitalization, symptom burden, and impaired health-related quality of life remain substantial. Historically, dialysis innovation has emphasized surrogate measures such as solute clearance and biochemical targets. Although these advances have improved treatment delivery, gains in patient-important outcomes-including survival, hospitalization, symptoms, and functional status-have been limited, suggesting diminishing returns from further optimization of traditional adequacy targets. Dialysis therapies should therefore be evaluated by their effects on clinical outcomes, patient-reported outcomes, safety, equity, sustainability, and value. This review assesses contemporary extracorporeal modalities and emerging technologies using an outcome-based framework incorporating implementation, health-system implications, and patient priorities. High-flux hemodialysis is the current standard of care but has not consistently been associated with lower all-cause mortality despite achievement of modern adequacy targets. Medium cut-off membranes, adsorption-based approaches, personalized schedules, and portable, wearable, or implantable technologies offer compelling physiologic rationales and may improve selected surrogate measures; however, evidence of meaningful clinical benefit remains limited. Among extracorporeal therapies, online hemodiafiltration has the strongest evidence base. Randomized trials and individual-participant-data meta-analyses indicate better survival with high-volume online hemodiafiltration versus high-flux hemodialysis, with supportive patient-reported and cost-effectiveness evidence. However, CONVINCE patients achieved high convection volumes; benefit is uncertain for those unable to reach these targets, and implementation depends on infrastructure, reimbursement, regulation, and quality assurance. Current evidence supports shifting dialysis innovation from surrogate endpoints toward outcomes that matter to patients. Physiologic plausibility and surrogate improvements alone should not justify widespread adoption. Future progress requires rigorous comparative-effectiveness research, implementation science, real-world evidence, routine integration of standardized patient-reported outcomes, and attention to environmental sustainability and equitable access. Aligning reimbursement, quality metrics, implementation, and policy with patient-level outcomes will be essential to translate technological advances into better care for people with kidney failure.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Nissenson AR, Hegbrant J, Maddux FW, et al. Hemodialysis Care: Evolving to Enhance Patient-Level Outcomes. J Am Soc Nephrol. 2026. PMID: 42771474. doi:10.1681/ASN.0000001286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。